Jade Biosciences, Inc. (JBIO) Financial Statements
Free cash flow over the same period: -$123.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
JBIOJade Biosciences, Inc.Follow JBIO — free
—
Price chart with a free account
- Market cap
- 927.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 15.0 | 38.6 | 64.2 | 53.2 | 93.1 | 136.7 | |
| Operating income | -23.0 | -53.2 | -81.4 | -74.6 | -113.5 | -164.7 | |
| Pre-tax income | -23.0 | -51.5 | -75.5 | -69.6 | -127.4 | -153.2 | |
| Income tax | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Net income | -23.0 | -51.5 | -75.5 | -69.6 | -127.4 | -153.2 | |
| Diluted EPS ($) | -1.87 | -2.10 | -2.87 | -2.44 | -3.19 | -2.05 | |
| Diluted shares (mn) | — | 24.5 | 26.3 | 28.6 | 31.4 | — |
USD millions · SEC XBRL
Jade Biosciences, Inc. — questions
- What is Jade Biosciences, Inc.'s net income?
- -$153.2M over the twelve months to 2026-06-30.
- What is Jade Biosciences, Inc.'s free cash flow?
- -$123.6M over the twelve months to 2026-06-30.
- What are Jade Biosciences, Inc.'s diluted earnings per share?
- $-2.05 over the twelve months to 2026-06-30.
Every figure on this page comes from Jade Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.